Cargando…
Identification of a TLR2 Inhibiting Wheat Hydrolysate
SCOPE: Wheat hydrolysates are used in medical nutrition to provide undernourished patients a readily digestible protein source, for instance to recover from chemotherapy‐induced intestinal mucosal inflammation. Since many hydrolysates of different sources can modulate the immune system, likely via T...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6646915/ https://www.ncbi.nlm.nih.gov/pubmed/30354027 http://dx.doi.org/10.1002/mnfr.201800716 |
_version_ | 1783437628243181568 |
---|---|
author | Kiewiet, Mensiena B. G. Dekkers, Renske van Gool, Martine P. Ulfman, Laurien H. Groeneveld, Andre Faas, Marijke M. de Vos, Paul |
author_facet | Kiewiet, Mensiena B. G. Dekkers, Renske van Gool, Martine P. Ulfman, Laurien H. Groeneveld, Andre Faas, Marijke M. de Vos, Paul |
author_sort | Kiewiet, Mensiena B. G. |
collection | PubMed |
description | SCOPE: Wheat hydrolysates are used in medical nutrition to provide undernourished patients a readily digestible protein source, for instance to recover from chemotherapy‐induced intestinal mucosal inflammation. Since many hydrolysates of different sources can modulate the immune system, likely via Toll‐like receptors (TLRs), it is hypothesized that also wheat hydrolysates might interact with TLR signaling, which could be a way to prevent intestinal inflammation and damage. METHODS AND RESULTS: The capacity of three wheat hydrolysates to modulate immunity by interfering with TLR signaling is determined. All wheat hydrolysates have TLR modulating effects but only one has strong TLR2 inhibiting effects, attenuating both TLR2/1 and TLR2/6 signaling in a reporter cell system. This is likely induced by direct TLR2‐ectodomain binding, as confirmed by ELISA. Furthermore, this TLR2 blocking hydrolysate reduces IL‐6 production in human dendritic cells. Application of reversed‐phase–ultra HPLC combined with MS reveals that the presence of peptide WQIPEQSR is associated with the observed TLR2 inhibiting capacity. CONCLUSION: The study demonstrates TLR2‐inhibiting capacities of a wheat hydrolysate. The findings provide a good start for further research to investigate whether this hydrolysate might contribute to the management of intestinal mucosal inflammation in cancer patients receiving chemotherapy. |
format | Online Article Text |
id | pubmed-6646915 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-66469152019-07-31 Identification of a TLR2 Inhibiting Wheat Hydrolysate Kiewiet, Mensiena B. G. Dekkers, Renske van Gool, Martine P. Ulfman, Laurien H. Groeneveld, Andre Faas, Marijke M. de Vos, Paul Mol Nutr Food Res Research Articles SCOPE: Wheat hydrolysates are used in medical nutrition to provide undernourished patients a readily digestible protein source, for instance to recover from chemotherapy‐induced intestinal mucosal inflammation. Since many hydrolysates of different sources can modulate the immune system, likely via Toll‐like receptors (TLRs), it is hypothesized that also wheat hydrolysates might interact with TLR signaling, which could be a way to prevent intestinal inflammation and damage. METHODS AND RESULTS: The capacity of three wheat hydrolysates to modulate immunity by interfering with TLR signaling is determined. All wheat hydrolysates have TLR modulating effects but only one has strong TLR2 inhibiting effects, attenuating both TLR2/1 and TLR2/6 signaling in a reporter cell system. This is likely induced by direct TLR2‐ectodomain binding, as confirmed by ELISA. Furthermore, this TLR2 blocking hydrolysate reduces IL‐6 production in human dendritic cells. Application of reversed‐phase–ultra HPLC combined with MS reveals that the presence of peptide WQIPEQSR is associated with the observed TLR2 inhibiting capacity. CONCLUSION: The study demonstrates TLR2‐inhibiting capacities of a wheat hydrolysate. The findings provide a good start for further research to investigate whether this hydrolysate might contribute to the management of intestinal mucosal inflammation in cancer patients receiving chemotherapy. John Wiley and Sons Inc. 2018-11-02 2018-12 /pmc/articles/PMC6646915/ /pubmed/30354027 http://dx.doi.org/10.1002/mnfr.201800716 Text en © 2018 The Authors. Published by WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Kiewiet, Mensiena B. G. Dekkers, Renske van Gool, Martine P. Ulfman, Laurien H. Groeneveld, Andre Faas, Marijke M. de Vos, Paul Identification of a TLR2 Inhibiting Wheat Hydrolysate |
title | Identification of a TLR2 Inhibiting Wheat Hydrolysate |
title_full | Identification of a TLR2 Inhibiting Wheat Hydrolysate |
title_fullStr | Identification of a TLR2 Inhibiting Wheat Hydrolysate |
title_full_unstemmed | Identification of a TLR2 Inhibiting Wheat Hydrolysate |
title_short | Identification of a TLR2 Inhibiting Wheat Hydrolysate |
title_sort | identification of a tlr2 inhibiting wheat hydrolysate |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6646915/ https://www.ncbi.nlm.nih.gov/pubmed/30354027 http://dx.doi.org/10.1002/mnfr.201800716 |
work_keys_str_mv | AT kiewietmensienabg identificationofatlr2inhibitingwheathydrolysate AT dekkersrenske identificationofatlr2inhibitingwheathydrolysate AT vangoolmartinep identificationofatlr2inhibitingwheathydrolysate AT ulfmanlaurienh identificationofatlr2inhibitingwheathydrolysate AT groeneveldandre identificationofatlr2inhibitingwheathydrolysate AT faasmarijkem identificationofatlr2inhibitingwheathydrolysate AT devospaul identificationofatlr2inhibitingwheathydrolysate |